Search

Your search keyword '"Hans Erik Johnsen"' showing total 398 results

Search Constraints

Start Over You searched for: Author "Hans Erik Johnsen" Remove constraint Author: "Hans Erik Johnsen"
398 results on '"Hans Erik Johnsen"'

Search Results

201. Cancer stem cells and the cellular hierarchy in haematological malignancies

202. Up-front fludarabine impairs stem cell harvest in multiple myeloma: report from an interim analysis of the NMSG 13/03 randomized placebo controlled phase II trial

205. Double vs. single high dose melphalan 200 mg/m2 and autologous stem cell transplantation for multiple myeloma: a region-based study in 484 patients from the Nordic area

207. High numbers of clonal CD19+ cells in the peripheral blood of a patient with multiple myeloma

208. [Complete remission after Rituximab treatment in refractory hairy cell leukemia]

209. A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy

210. Complete remission after Rituximab treatment in refractory hairy cell leukemia

211. Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of a randomized comparison with vincristine, doxorubicin, and dexamethasone

212. Comparison of different culture conditions for human mesenchymal stromal cells for clinical stem cell therapy

213. MicroRNA expression in nodal and extranodal diffuse large B-cell lymphoma

218. Subtyping of B-Cell Malignancies By B-Cell Subset Associated Gene Signatures (BAGS), Generated from Human Primary and Secondary Lymphoid Organs

219. Inherited Inflammatory Response Genes Are Associated with B-Cell Non-Hodgkin’s Lymphoma Risk and Survival

220. Flow cytometry comparison of CD34+ subsets in bone marrow and peripheral blood after priming with glycosylated or non-glycosylated rhG-CSF

221. Magnetic resonance investigation of bone marrow following priming and stem cell mobilization

222. Serum YKL-40 concentrations in newly diagnosed multiple myeloma patients and YKL-40 expression in malignant plasma cells

223. [Acute lymphoblastic leukaemia in Danish children and young people 10 to 19 years of age. Should young adults with acute lymphoblastic leukaemia be treated in the same way as children?]

224. Intramyocardial injection of vascular endothelial growth factor-A165 plasmid followed by granulocyte-colony stimulating factor to induce angiogenesis in patients with severe chronic ischaemic heart disease

225. Quality assessment of autografting by probability evaluation: model estimation by clinical end-points in newly diagnosed multiple myeloma patients

226. Impaired functionality and phenotypic profile of dendritic cells from patients with multiple myeloma

227. Stem cell mobilization induced by subcutaneous granulocyte-colony stimulating factor to improve cardiac regeneration after acute ST-elevation myocardial infarction: result of the double-blind, randomized, placebo-controlled stem cells in myocardial infarction (STEMMI) trial

228. Impact of age on survival after intensive therapy for multiple myeloma: apopulation-based study by the Nordic Myeloma Study Group

229. Changes in circulating mesenchymal stem cells, stem cell homing factor, and vascular growth factors in patients with acute ST elevation myocardial infarction treated with primary percutaneous coronary intervention

230. Microalbuminuria is associated with impaired glomerular permselectivity in lymphoma patients

231. Multiplex reverse transcription polymerase chain reaction screening in acute myeloid leukemia detects cytogenetically unrevealed abnormalities of prognostic significance

232. Serum levels of inflammatory cytokines at diagnosis correlate to the bcl-6 and CD10 defined germinal centre (GC) phenotype and bcl-2 expression in patients with diffuse large B-cell lymphoma

233. In-stent neo-intimal hyperplasia after stem cell mobilization by granulocyte-colony stimulating factor Preliminary intracoronary ultrasound results from a double-blind randomized placebo-controlled study of patients treated with percutaneous coronary intervention for ST-elevation myocardial infarction (STEMMI Trial)

234. Prediction of haemorrhage in the early stage of acute myeloid leukaemia by flow cytometric analysis of platelet function

235. Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors

236. Impaired circulating myeloid DCs from myeloma patients

239. Clinical application of dendritic cells in cancer vaccination therapy

240. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial

241. Impact of high-dose chemotherapy on antigen-specific T cell immunity in breast cancer patients. Application of new flow cytometric method

242. Efficacy and safety of CD34-selected and CD19-depleted autografting in multiple myeloma patients: a pilot study

243. Hypereosinophilic syndrome treated with α-interferon and granulocyte colony-stimulating factor but complicated by nephrotoxicity

244. A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis

245. Prognostic Impact of Extranodal Diffuse Large B-Cell Lymphoma in the Era of Immunochemotherapy and PET/CT Staging

246. Role of Bone Marrow Biopsy in the Staging of Diffuse Large B-Cell Lymphoma in the PET/CT Era

247. Technical aspects and clinical impact of hematopoietic progenitor subset quantification

248. Highly purified CD34+ cells isolated using magnetically activated cell selection provide rapid engraftment following high-dose chemotherapy in breast cancer patients

249. Reduced bone marrow stem cell pool and progenitor mobilisation in multiple myeloma after melphalan treatment

Catalog

Books, media, physical & digital resources